BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 2, 2026
Breaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreakBreaking News: Ongoing coverage of the Ebola outbreak
Home » Topics » BioWorld Science, Respiratory

BioWorld Science, Respiratory
BioWorld Science, Respiratory RSS Feed RSS

Lungs
Respiratory

Financing at Tribune Therapeutics supports targeting CCN protein family to treat fibrosis

March 27, 2025
Tribune Therapeutics AB has raised €37 million (US$40 million) in seed and series A funding to advance a portfolio of therapies targeting central drivers of scar tissue formation.
Read More
Respiratory

Haisco Pharmaceutical identifies new LPAR1 antagonists

March 25, 2025
Haisco Pharmaceutical Group Co. Ltd. has described lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, benign prostate hyperplasia, multiple sclerosis, neuronal injury and neuralgia.
Read More
Respiratory

Roche discloses new NLRP3 inflammasome inhibitors

March 25, 2025
Scientists from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented NLRP3 inflammasome and interleukin-1β (IL1B; IL-1β) release inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, Alzheimer’s and Parkinson’s diseases.
Read More
Immune

MTH1 inhibition for treating allergic airway inflammation

March 25, 2025
Asthma affects about 300 million people worldwide. Inflammation in asthma may drive irreversible airway remodeling due to subepithelial fibrosis, extracellular matrix degradation and increased smooth muscle cell mass levels, among others. In vitro and in vivo assays were performed to test MutT homolog 1 (MTH1) as a therapeutic target in allergic airway inflammation.
Read More
Lungs anatomy
Respiratory

Efficient TGF-β mRNA delivery to mouse lung parenchyma via ionizable amphiphilic Janus dendrimers

March 21, 2025
Several lung conditions, such as acute lung injury, require the targeted delivery of pharmacological agents to the lower lung. However, the administration of complex biologics, such as anti-inflammatory cytokine mRNA, to the injury site in the lower lungs is particularly challenging, frequently leading to poor specificity and uneven distribution.
Read More
Lungs
Respiratory

LMO7 as therapeutic target to block profibrotic fibroblast polarization in IPF

March 19, 2025
Researchers from Shanghai Jiao Tong University and affiliated organizations have published their findings from studies that aimed to investigate the pathogenesis of idiopathic pulmonary fibrosis (IPF) and identify novel regulators of the disease.
Read More
Illustration of alveoli and lungs
Respiratory

Smsbiotech’s small mobile stem cell therapy cleared to enter clinic for COPD

March 19, 2025

Smsbiotech Inc. has gained clearance in Australia to begin a phase I trial of its small mobile stem (SMS) cell therapy for chronic obstructive pulmonary disease (COPD). 


Read More
AI-generated image of illustration of MRI of lungs with fibrosis
Respiratory

Adenine base editing corrects G542X mutation in CFTR in patient organoid models

March 13, 2025
Cystic fibrosis (CF) is a life-threatening autosomal recessive disease affecting over 160,000 people worldwide. CF is caused by loss-of-function mutations in the CF transmembrane conductance regulator (CFTR) that mediates Cl and HCO3 anion transport.
Read More
Lungs wireframe illustration
Respiratory

OC-STAMP identified as a potential diagnostic biomarker and therapeutic target for silicosis

March 13, 2025
Silicosis, resulting from prolonged exposure to free crystalline silica dust, is an occupational disease characterized by silica nodules and extensive lung tissue fibrosis. The etiology of silicosis remains unclear, challenging early detection and effective treatment.
Read More
Genome concept art.
Infection

Study looks to noncoding gene variants for new drug targets

March 12, 2025
By Nuala Moran
A new multi-omics approach to unpicking how noncoding gene variants influence the development of common chronic diseases has identified tens of thousands of instances where variants have an impact on gene expression levels and gene splicing, the post-transcriptional modification that allows one gene to code for multiple proteins.
Read More
Previous 1 2 … 9 10 11 12 13 14 15 16 17 … 693 694 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 2, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • Healthy (left) vs. cancerous bone marrow

    BMS’ mezigdomide doubles PFS in multiple myeloma

    BioWorld
    Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
  • Antibodies attacking cancer cell

    ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal

    BioWorld
    Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing